Evidence map›Paper›PMID 30392411›Full record

ArticleThe American journal of psychiatry2019

Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.

Jian-Ping Zhang, Delbert Robinson, Jin Yu, Juan Gallego, W Wolfgang Fleischhacker, Rene S Kahn, Benedicto Crespo-Facorro, Javier Vazquez-Bourgon, John M Kane, Anil K Malhotra and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Patient Perspectives on Psychiatric Polygenic Risk Scores in Reproductive Decision-Making and Polygenic Embryo Screening.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. The impact of collider bias on genetic prediction in psychotic disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jian-Ping ZhangFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Delbert RobinsonFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Jin YuFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Juan GallegoFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
W Wolfgang FleischhackerFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Rene S KahnFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Benedicto Crespo-FacorroFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Javier Vazquez-BourgonFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
John M KaneFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Anil K MalhotraFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.
Todd LenczFrom the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.

Funding

Striatal D2/D3 Dopamine receptor availability in first episode schizophreniaP50MH080173 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI KANE, JOHN M · 2008 to 2012
$10.4M
Trials Operation Unit (OPERATIONS CORE)P30MH090590 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI KANE, JOHN M · 2010 to 2014
$7.9M
3/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109536 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHARNEY, ALEXANDER W, HUCKINS, LAURA MARIANNE · 2016 to 2020
$2.7M
Pharmacogenetics of Antipsychotic-Induced Side Effects with a Focus on Weight GaiK23MH097108 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI ZHANG, JIANPING · 2012 to 2016
$906k
Pharmacogenetic Prediction of Antipsychotic Induced Weight GainR21MH099868 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI LENCZ, TODD · 2013 to 2014
$463k
NIMH NIH HHS K23 MH097108NIMH NIH HHS P30 MH090590NIMH NIH HHS P50 MH080173NIMH NIH HHS R21 MH099868NIMH NIH HHS U01 MH109536
6 · The paper itself

Abstract

objectivePharmacogenomic studies of antipsychotics have typically examined effects of individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome-wide association studies (GWAS) can quantify the influence of thousands of common alleles of small effect in a single measure. The authors examined whether PRSs for schizophrenia were predictive of antipsychotic efficacy in four independent cohorts of patients with first-episode psychosis (total N=510).

methodAll study subjects received initial treatment with antipsychotic medication for first-episode psychosis, and all were genotyped on standard single-nucleotide polymorphism (SNP) arrays imputed to the 1000 Genomes Project reference panel. PRS was computed based on the results of the large-scale schizophrenia GWAS reported by the Psychiatric Genomics Consortium. Symptoms were measured by using total symptom rating scales at baseline and at week 12 or at the last follow-up visit before dropout.

resultsIn the discovery cohort, higher PRS significantly predicted higher symptom scores at the 12-week follow-up (controlling for baseline symptoms, sex, age, and ethnicity). The PRS threshold set at a p value <0.01 gave the strongest result in the discovery cohort and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted greater posttreatment symptoms in the combined replication analysis and was individually significant in two of the three replication cohorts. Across the four cohorts, PRS was significantly predictive of adjusted 12-week symptom scores (pooled partial r=0.18; 3.24% of variance explained). Patients with low PRS were more likely to be treatment responders than patients with high PRS (odds ratio=1.91 in the two Caucasian samples).

conclusionsPatients with higher PRS for schizophrenia tended to have less improvement with antipsychotic drug treatment. PRS burden may have potential utility as a prognostic biomarker.

Indexed as

Psychotic DisordersSchizophreniaAdultAntipsychotic AgentsEpisode of CareFemaleGenome-Wide Association StudyHumansMaleMultifactorial InheritancePredictive Value of TestsPrognosisPsychopathologyRisk AssessmentSchizophrenic PsychologyTreatment OutcomeAntipsychotic AgentsAntipsychoticsFirst Episode PsychosisPolygenic Risk ScoreSchizophrenia

Identifiers

PMID30392411
PMCPMC6461047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.